Ivermectin is a prescription antiparasitic drug sold as Stromectol and generic equivalents, and it is not available for legitimate human use without a clinician's order. In the United States, licensed pharmacies dispense it only against a valid prescription, and FDA-approved labeling covers specific parasitic infections rather than viral illness. The drug's real pharmacology, its narrow therapeutic window, and the genuine risks of unregulated sourcing matter far more than any single storefront. This guide explains how ivermectin works at the receptor level, where legitimate supply actually comes from, and why the unregulated market is a distinct hazard.
Mechanism: Glutamate-Gated Chloride Channels
Ivermectin belongs to the avermectin family, macrocyclic lactones derived from Streptomyces avermitilis fermentation. Its target in parasites is a glutamate-gated chloride channel, a pentameric receptor that opens in response to glutamate and lets chloride ions flood the cell. Ivermectin binds at the interface between channel subunits and locks the pore open. The resulting chloride influx hyperpolarizes the cell membrane, silencing pharyngeal pumping and motor coordination in nematodes and arthropods.
The selectivity story is the key mechanistic detail. These glutamate-gated channels are absent in mammals, so the drug spares human neurons at therapeutic concentrations. Mammalian GABA-A receptors are related but far less sensitive, and that difference defines the safety margin. The blood-brain barrier is the second gatekeeper: P-glycoprotein pumps ivermectin out of the central nervous system. When that pump is overwhelmed or genetically deficient, the margin collapses.
Absorption matters clinically. Oral ivermectin is lipophilic, distributes widely into tissue, and has a plasma half-life of roughly 12 to 36 hours depending on formulation. Peak levels arrive in about 4 hours. It is metabolized mainly by CYP3A4, which is why strong inhibitors of that enzyme can raise exposure. This is a pharmacologically active drug with real drug interactions, not an inert supplement.
Quantified Context: Doses, Mass, and Market Scale
Human ivermectin dosing is weight-based, and the total milligram burden is small. A typical adult course for onchocerciasis or strongyloidiasis is a single 150 to 200 microgram per kilogram dose, which for an 80 kg adult is roughly 12 to 16 mg. Scabies regimens often use repeated doses at intervals. These are clinician decisions, and this article deliberately does not supply dosing schedules.
The mass difference between human and veterinary products is the most important number in this entire topic. Cattle and horse formulations are packaged for animals weighing hundreds of kilograms. A tube or paste intended for a 500 kg horse contains far more drug than any human dose. Accidental ingestion of veterinary paste has produced measurable overdose, and the FDA has documented serious neurological events from such exposure [FDA].
Supply is not scarce in a manufacturing sense. Ivermectin is on the World Health Organization Model List of Essential Medicines, and generic manufacturers produce it at low cost for mass drug administration programs. The WHO has distributed billions of doses through onchocerciasis and lymphatic filariasis campaigns [WHO]. The access problem is regulatory, not industrial: legitimate channels route the drug through prescriptions, while gray-market sellers route it around them.
Pricing in legitimate channels varies with formulation and pharmacy, and it is not stable enough to state as a fixed figure here. What can be said with confidence is that certified generic tablets from licensed pharmacies cost far less per dose than the marked-up "research use" vials sold online, which frequently contain unverified content.
Edge Cases: Where the Margin Disappears
The P-glycoprotein knockout scenario is the canonical edge case. Dogs with the MDR1 mutation suffer fatal neurotoxicity from ivermectin doses that are safe in other breeds, and the same transporter biology applies to humans with rare variants or drug-induced pump inhibition. Concurrent use of strong CYP3A4 inhibitors or P-glycoprotein inhibitors can push plasma levels upward. This is a genuine pharmacokinetic interaction, not a hypothetical.
Body weight extremes matter. Dosing is per kilogram, so very low body weight or obesity changes the absolute milligram amount and the volume of distribution. Clinicians adjust for this; a self-sourced dose from a foreign label cannot.
Pregnancy and early childhood are separate categories where the risk-benefit calculus is clinician territory. Lactation is another. The drug is generally regarded as compatible in specific indications under supervision, but the operative word is supervision. None of this is self-titratable.
Counterintuitive detail: ivermectin's reputation for safety rests on decades of mass administration in healthy adults with onchocerciasis. That population excludes the exact people most likely to self-medicate with unverified product—those with comorbidities, polypharmacy, and compromised barriers. The safety data do not transfer to the gray-market user.
Misconceptions: Antiviral Claims and the Sourcing Trap
The largest misconception is that ivermectin is an antiviral. Mechanistically, its known target is the parasite chloride channel. In vitro studies reporting activity against various viruses used concentrations far above achievable human plasma levels, and the clinical trial record for COVID-19 does not support benefit. The FDA has stated that ivermectin is not authorized or approved for the prevention or treatment of COVID-19 [FDA], and major trials including ACTIV-6 found no meaningful effect on symptom duration. The mechanism simply does not map onto viral replication in humans.
The second misconception is that "Stromectol" is a special branded product distinct from generic ivermectin. It is a brand name for the same molecule. Generic equivalents are pharmacologically identical when manufactured to pharmacopeial standards. Paying a premium for a specific label does not change the pharmacology.
The third is that buying from an online "research chemical" store is a minor risk. It is not.
Unverified content: products have tested as blank, underdosed, or containing unrelated compounds. Veterinary-grade concentration: animal formulations carry far higher milligram loads per unit. No lot traceability: you cannot verify sterility, stability, or origin. Interaction blindness: no pharmacist screens for CYP3A4 or P-glycoprotein interactions. Legal exposure: importing unapproved prescription drugs can violate federal law. Delay of real care: self-treatment substitutes for diagnosis of the actual condition.
The sourcing trap compounds the pharmacology trap. A person who buys unregulated ivermectin has neither the verified molecule nor the verified dose.
Practical Actions: Legitimate Access Pathways
The legitimate answer to where to buy ivermectin is a licensed pharmacy against a prescription. Concrete steps:
First, get a diagnosis. The conditions ivermectin legitimately treats—strongyloidiasis, onchocerciasis, scabies, some lice infestations—have recognizable presentations, and a clinician confirms them. Second, obtain a prescription from a licensed prescriber in your jurisdiction. Third, fill it at a licensed pharmacy, community or mail-order, that verifies the prescription. Fourth, ask the pharmacist to screen for interactions with your current medications, specifically CYP3A4 and P-glycoprotein inhibitors. Fifth, keep the manufacturer lot number and report any adverse event to the appropriate national reporting system.
For clinicians and patients evaluating access, the reconciliation of thresholds is straightforward: the regulatory threshold (prescription required), the pharmacological threshold (weight-based milligram dose), and the safety threshold (P-glycoprotein and CYP3A4 status) must all be satisfied. A product that satisfies only the first is not access; it is exposure.
Comparison of access routes:
| Route | Verification | Interaction screening | Legal status | Risk level |
|---|---|---|---|---|
| Licensed pharmacy with prescription | Lot traceable | Pharmacist review | Compliant | Low |
| Telehealth prescriber plus pharmacy | Lot traceable | Variable | Compliant | Low to moderate |
| Foreign online pharmacy | Uncertain | None | Often noncompliant | Moderate to high |
| Veterinary supply store | Animal-grade | None | Noncompliant for human use | High |
| "Research chemical" vendor | None | None | Noncompliant | Very high |
Time course of a legitimate episode:
| Stage | Typical timing | What happens |
|---|---|---|
| Presentation | Day 0 | Symptoms prompt clinical evaluation |
| Diagnosis | Days to weeks | Stool, skin, or serologic testing confirms indication |
| Prescription | Same visit or shortly after | Clinician sets weight-based dose |
| Dispensing | Same day to days | Licensed pharmacy verifies and screens |
| Treatment | Per regimen | Single or repeated doses as directed |
| Follow-up | Weeks to months | Efficacy and adverse-event check |
Limitations: What the Evidence Does Not Cover
Several gaps deserve honest statement. The clinical trial literature on ivermectin is dominated by parasitic disease endpoints; extrapolation to other conditions is not supported by mechanism or by trials. Long-term safety data in polypharmacy patients are thinner than the mass-administration safety record suggests. The gray-market product landscape changes constantly, so specific vendor claims cannot be verified here.
The most important limitation is epistemic: this article explains pharmacology and access pathways, but it cannot determine whether ivermectin is appropriate for any individual. That determination requires a clinician who knows the patient's history, medications, and diagnostic results.
Ivermectin is a well-characterized, genuinely useful antiparasitic with a real mechanism, a measurable therapeutic window, and a legitimate supply chain. The keyword question—where to buy Stromectol—has a boring answer: a licensed pharmacy, with a prescription, after a diagnosis. The interesting science is in the chloride channel and the P-glycoprotein barrier that makes the margin real.
This article is general educational information about pharmacology and drug access, not a diagnosis, treatment plan, or prescribing recommendation. It does not promise any outcome from any product. Readers should consult a qualified local clinician or pharmacist for personal medical decisions, and contact local emergency services for any suspected overdose or serious adverse reaction.